Programme | Local host | Faculty | Venue | Sponsors | CME Accreditation
DEB & cTACE in Primary and Secondary Liver Cancer, Munich/DE, June 6-7, 2019
HCC is a common type of cancer with increasing incidence. Intra-arterial therapies are often part of the treatment algorithm and several intra-arterial treatment options are available today, including C-TACE, DEB-TACE, balloon TACE and TARE. This Clinical Procedure Training course gives experienced physicians the opportunity to fine-tune their practical skills and learn more about current treatment options for various stages of HCC and liver metastatic disease.
Theoretical presentations will be organised to allow participants to understand the staging and treatment algorithm of HCC and metastatic liver disease. Hands-on sessions will then provide the opportunity to handle current devices and to learn about the most advanced technologies fit for intra-arterial therapy. Due to the complexity of treating HCC and liver metastases, collaboration between medical oncologists, surgeons and radiation therapists is needed. A section of the programme will be dedicated to imaging follow-up and treatment evaluation. Highly experienced physicians will present complications and lessons learned.
We hope you can join us at the prestigious Hospital Barmherzige Brueder Munich for this exciting course!
Thursday, June 6, 2019
08:15-08:45
Registration
08:45-09:00
Welcome
09:00-10:40
TACE for HCC
HCC overview of staging systems (BCLC, HKLC, others)
TACE in HCC: Patient selection to maximise outcomes and avoid complication
TACE HCC: Rationale to combine with systemic therapies, results and possible future development
Is there any indication for TACE in advanced HCC patients?
10:40-11:00
Coffee Break
11:00-12:00
TACE for Liver Metastases
Parallel: Simulator/Flow Model Training
TACE for NET: Patient selection, treatment outcomes and systemic competitors
DEB-TACE for other metastases (colorectal, breast, …): Patient selection, technical points, treatment schedule and follow-up, systemic competitors
12:00-12:30
TACE Technique
Parallel: Simulator/Flow Model Training
Conventional TACE is better
Drug eluting microspheres TACE is better
12:30-14:00
Lunch
14:00-16:00
TACE in Clinical Practice I
Parallel: Simulator/Flow Model Training
TACE for HCC in clinical practice. Treatment schedule, clinical and biological follow-up. When to stop? When to retreat?
How to evaluate response to TACE: RECIST, mRECIST, rRECIST, Choi?
TACE: Lesson learned from the worst complication I ever had (from 6 speakers)
Discussion
16:00-16:15
Coffee Break
16:15-18:15
Live Case #1: C-TACE
Parallel: Simulator/Flow Model Training
Friday, June 7, 2019
08:30-09:30
TACE in Clinical Practice II
Parallel: Simulator/Flow Model Training
TACE + ablation: For whom, when, and how?
Balloon TACE: A new kid on the block
Is there a role for SIRT within the BCLC system?
09:30-09:45
Coffee Break
09:45-12:15
Live Case 2: DEB-TACE
Parallel: Simulator/Flow Model Training
12:15-13:15
Lunch
13:15-15:15
Hands-On Training
Vascular flow model using drug-eluting beads
Building the right suspension
Which microcatheter and which wire?
Transradial, transfemoral and how to close
15:15-16:00
Workshop
Tumour board
16:00
Certificate of Attendance
Local host
T.F. Jakobs, Munich (DE)
Faculty
T. de Baère, Villejuif (FR)
B. Gebauer, Berlin (DE)
T.K. Helmberger, Munich (DE)
R. Iezzi, Rome (IT)
T.F. Jakobs, Munich (DE)
G. Maleux, Leuven (BE)
B. Meyer, Hannover (DE)
O. Pellerin, Paris (FR)
B. Peynircioglu, Ankara (TR)
M. Seidensticker, Munich (DE)
Venue
Hospital Barmherzige Brueder Munich
Romanstraße 93
80639 Munich
Germany
CME Accreditation
The ESIR 2019: DEB & cTACE in Primary and Secondary Liver Cancer, Munich, Germany, 06/06/2019-07/06/2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 13 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.